AB ScienceXPAR:AB +1.86%59 Gross Margin % is 125.49% as of Dec. 2025, which is 38% above its 10-year median of 90.76. GuruFocus rates XPAR:AB with a GF Score™ of 59/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 935 Drug Manufacturers companies, AB Science ranks better than 94.97% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. AB Science's Gross Profit for the
six
months ended in Dec. 2025 was €0.83 Mil. AB Science's Revenue for the
six
months ended in Dec. 2025 was €0.66 Mil. Therefore, AB Science's Gross Margin % for the quarter that ended in Dec. 2025 was 125.49%.
Warning Sign:
AB Science gross margin has been in long-term decline. The average rate of decline per year is -1.4%.
The historical rank and industry rank for AB Science's Gross Margin % or its related term are showing as below:
XPAR:AB'
s Gross Margin % Range Over the Past 10 Years
Min: 60.52 Med: 90.76 Max: 116.42
Current: 83.31
During the past 13 years, the highestGross Margin % of AB Science was 116.42%. The lowest was 60.52%. And the median was 90.76%.
XPAR:AB's Gross Margin % is ranked better than 94.97% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs XPAR:AB: 83.31
AB Science had a gross margin of 125.49% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for AB Science was -1.40% per year.
AB Science (XPAR:AB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
AB Science had a gross margin of 125.49% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
AB Science Gross Margin % Related Terms
AB Science Gross Margin % Historical Data
* Premium members only.
The historical data trend for AB Science's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:AB vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's Gross Margin % distribution charts can be found below:
* The bar in red indicates where AB Science's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
AB Science (XPAR:AB) has a Gross Margin % of 125.49% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on AB Science and its competitors. This is 38% above median its historical median of 90.76. Over the past decade, AB Science's Gross Margin % has ranged from 60.52 to 116.42. According to the industry distribution chart, AB Science ranks #47 out of 935 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is AB Science's Gross Margin % too high?
AB Science's current Gross Margin % of 125.49% is 38% above median its 10-year median of 90.76. Over the past 10 years, this metric has ranged from a low of 60.52 to a high of 116.42. The Drug Manufacturers industry median Gross Margin % is 48.54. AB Science's value of 125.49% is 158.5% above this industry median. Based on the distribution chart, AB Science ranks #47 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AB Science has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AB Science's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #47 out of 935 companies for Gross Margin %. This places AB Science in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. AB Science's value of 125.49% is 158.5% above this benchmark. Historically, AB Science's own Gross Margin % has ranged from 60.52 to 116.42 over the past decade. While the company's 10-year median is 90.76 vs. the industry median of 48.54, AB Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AB Science's current Gross Margin % of 125.49% is 158.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current Gross Margin % is 125.49%, which is 38% above median its own 10-year median of 90.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (XPAR:AB) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.87 — trading 40.5% below its estimated fair value. The current Gross Margin % is 125.49%, which is 38% above median its 10-year median of 90.76 and 158.5% above the Drug Manufacturers industry median of 48.54. AB Science's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For AB Science (XPAR:AB), the current Gross Margin % is 125.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (XPAR:AB) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of €0.87 is trading 40.5% below its estimated GF Value™ of €1.47.
GuruFocus considers AB Science to be Possible Value Trap.
Key valuation signals for XPAR:AB:
Gross Margin %: 125.49% (38% above median its 10-year median of 90.76)
GF Value™: €1.47 vs. price of €0.87 (40.5% below fair value)
Industry Position: 158.5% above the Drug Manufacturers median (#47 of 935)
No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
59GF Score
Get the complete analysis for XPAR:AB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:AB has been successfully added to your 
